Loading...
Loading...
India's everolimus imports from SINGAPORE total $1.4K across 3 shipments from 2 foreign suppliers. SPRING BIO SOLUTION PTE LTD leads with $687 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ZENRISE CLINICAL RESEARCH PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for everolimus โ a concentrated sourcing relationship with select suppliers from SINGAPORE.

SPRING BIO SOLUTION PTE LTD is the leading Everolimus supplier from SINGAPORE to India, with import value of $687 across 2 shipments. The top 5 suppliers โ SPRING BIO SOLUTION PTE LTD, SPRING BIO SOLUTION PTE LIMITED โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SPRING BIO SOLUTION PTE LTD | $687 | 2 | 50.3% |
| 2 | SPRING BIO SOLUTION PTE LIMITED | $680 | 1 | 49.7% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ZENRISE CLINICAL RESEARCH PRIVATE LIMITED | $687 | 1 | 50.3% |
| 2 | ADMERUS BIOSCIENCES PRIVATE LIMITED | $680 | 1 | 49.7% |
| 3 | MYLAN LABORATORIES LIMITED |
SINGAPORE โ India trade corridor intelligence
As of April 2026, the Singapore to India trade corridor remains active, with shipments of pharmaceutical formulations containing Everolimus continuing to arrive. Port congestion at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra has been minimal, ensuring timely deliveries. Freight rates have stabilized, and the exchange rate between the Indian Rupee (INR) and Singapore Dollar remains favorable for trade. These factors contribute to a smooth and efficient import process for Singapore-origin pharmaceutical products.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. This initiative may impact the volume of finished formulation imports from Singapore, as domestic production increases. Import substitution policies are being implemented to encourage local manufacturing, potentially leading to a decrease in imports of certain pharmaceutical products. However, the demand for specialized formulations not produced domestically may continue to sustain imports from Singapore.
| $0 |
| 1 |
| 0.0% |
India and Singapore share a robust trade relationship, with ongoing Free Trade Agreement (FTA) negotiations aimed at enhancing bilateral trade, including pharmaceutical products. Mutual recognition of Good Manufacturing Practice (GMP) certifications has streamlined the import process for Singapore-origin goods. Pharmaceutical trade facilitation measures, such as simplified documentation and faster clearance procedures, have been implemented to promote smoother trade flows between the two nations.
The landed cost of importing Everolimus formulations from Singapore to India includes several components:
Per-unit estimates can be calculated by dividing the total landed cost by the number of units imported.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Everolimus into India requires compliance with the Drug and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organisation (CDSCO) mandates that all imported drugs be registered and approved. The registration process involves submitting an application in Form 40 or 41, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The application must include details such as the product's composition, manufacturing process, and stability data. The timeline for import drug registration can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory workload. For formulations under HS Code 30049049, specific requirements include providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data demonstrating compliance with International Council for Harmonisation (ICH) guidelines, particularly for Zone IV conditions.
Imported pharmaceutical formulations containing Everolimus must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including accelerated and long-term studies, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported goods. The testing process can take several weeks, and any discrepancies or failures in quality standards may lead to shipment rejection or delays.
Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting pharmaceutical imports. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Singapore have facilitated smoother trade relations, including mutual recognition of GMP certifications, which may expedite the import process for Singapore-origin goods. However, these agreements also emphasize the need for compliance with stringent quality and regulatory standards, ensuring that imported products meet Indian requirements.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Everolimus formulations to meet the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as certain tablet strengths or combination therapies, may not be produced locally, necessitating imports. The domestic capacity to produce Everolimus formulations is limited, leading to a dependency on imports to fulfill market needs. The market size for Everolimus formulations in India is substantial, with a growing number of patients requiring these treatments, thereby driving the demand for imported products.
The import duty structure for pharmaceutical formulations under HS Code 30049049 includes a Basic Customs Duty (BCD) of 10%. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in an effective duty rate of 11%. Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, which can vary based on the product and its classification. There are no specific exemptions or concessional duties for Singapore-origin goods under this HS Code. Anti-dumping duties are not currently applicable to Everolimus formulations imported from Singapore. The total landed duty percentage combines these components, affecting the final cost of imported goods.
India sources Everolimus formulations from Singapore due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and established trade relations. Singapore's competitive advantages include the production of patented formulations and specialized dosage forms that may not be available from other suppliers. While other countries like China, Germany, and the United States also export Everolimus formulations to India, Singapore's share in this market is notable due to its consistent quality and reliability.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Everolimus formulations from Singapore due to the availability of patented formulations and specialized dosage forms not produced domestically. Singapore's adherence to international quality standards and its established reputation in pharmaceutical manufacturing make it a reliable source for these products. The importation of these formulations ensures that Indian patients have access to the latest and most effective treatments for conditions requiring Everolimus.
When compared to other origins such as China, the European Union, and the United States, Singapore offers competitive advantages in terms of quality, regulatory compliance, and reliability. Singapore's pharmaceutical products are known for meeting stringent international standards, which is crucial for the Indian market. While other countries may offer lower prices, Singapore's consistent quality and adherence to regulatory requirements provide a unique advantage in the Indian market.
Indian importers face several supply chain risks when sourcing Everolimus formulations from Singapore. These include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but potential risks remain due to geopolitical factors or global supply chain disruptions. Diversifying suppliers and maintaining adequate inventory levels can mitigate some of these risks.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Everolimus suppliers from SINGAPORE to India include SPRING BIO SOLUTION PTE LTD, SPRING BIO SOLUTION PTE LIMITED. The leading supplier is SPRING BIO SOLUTION PTE LTD with import value of $687 USD across 2 shipments. India imported Everolimus worth $1.4K USD from SINGAPORE in total across 3 shipments.
India imported Everolimus worth $1.4K USD from SINGAPORE across 3 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Everolimus sourced from SINGAPORE include ZENRISE CLINICAL RESEARCH PRIVATE LIMITED, ADMERUS BIOSCIENCES PRIVATE LIMITED, MYLAN LABORATORIES LIMITED. The largest buyer is ZENRISE CLINICAL RESEARCH PRIVATE LIMITED with $687 in imports across 1 shipments.
The total value of Everolimus imports from SINGAPORE to India is $1.4K USD, across 3 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Verified Shipments
2 suppliers, 3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists